LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: Dietary consumption of tea and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

    Thomas, Robert / Greef, Basma / McConnachie, Alex / Stanley, Bethany / Williams, Madeleine

    British journal of nutrition. 20222021 Aug. 28 13, Sept. 28 13, v. 128, no. 4

    2022  

    Abstract: Tea contains polyphenols such as flavonoids, anthocyanidins, flavanols and phenolic acids which in laboratory studies have reported to promote antioxidant enzyme formation, reduces excess inflammation, slow cancer cell proliferation and promote apoptosis. ...

    Abstract Tea contains polyphenols such as flavonoids, anthocyanidins, flavanols and phenolic acids which in laboratory studies have reported to promote antioxidant enzyme formation, reduces excess inflammation, slow cancer cell proliferation and promote apoptosis. Evidence from epidemiological studies on the effect of tea consumption on prostate cancer (CaP) incidence has been conflicting. We analysed data from 25 097 men within the intervention arm of the 155 000 participant Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Histologically confirmed cases of prostate cancer were reported in 3088 men (12·3 %) during the median 11·5 year follow-up. Tea consumption was assessed with a FFQ. Baseline characteristics were compared between groups using χ² and Kruskal–Wallis tests. Cox regression models were used to assess associations between tea intake and CaP incidence. There was no statistical difference between the risk of CaP between men who never drank tea to those who drank tea at any quantity. Amongst tea drinkers, those in the highest third of consumption group had a small but significantly lower risk compared with those in the lowest third (11·2 % v. 13·2 % hazard ratio 1·16; (95 % CI 1·05, 1·29), P = 0·004). This pattern persisted with adjustments for demographics and lifestyle. In conclusion, among tea drinkers, there was a small positive association between drinking tea and a reduced risk of prostate cancer. It does not support starting to drink tea, if men previously did not, to reduce the risk. Further research is needed to establish whether tea is justified for future prospective nutritional intervention studies investigating CaP prevention.
    Keywords anthocyanidins ; antioxidant enzymes ; apoptosis ; cell proliferation ; demographic statistics ; flavanols ; hazard ratio ; inflammation ; lifestyle ; lungs ; neoplasm cells ; nutrition ; nutritional intervention ; ovarian neoplasms ; polyphenols ; prostatic neoplasms ; regression analysis ; risk ; risk reduction ; tea
    Language English
    Dates of publication 2022-0828
    Size p. 653-658.
    Publishing place Cambridge University Press
    Document type Article
    ZDB-ID 280396-3
    ISSN 1475-2662 ; 0007-1145
    ISSN (online) 1475-2662
    ISSN 0007-1145
    DOI 10.1017/S0007114521003664
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article ; Online: Dietary consumption of tea and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

    Thomas, Robert / Greef, Basma / McConnachie, Alex / Stanley, Bethany / Williams, Madeleine

    The British journal of nutrition

    2021  , Page(s) 1–6

    Abstract: Tea contains polyphenols such as flavonoids, anthocyanidins, flavanols and phenolic acids which in laboratory studies have reported to promote antioxidant enzyme formation, reduces excess inflammation, slow cancer cell proliferation and promote apoptosis. ...

    Abstract Tea contains polyphenols such as flavonoids, anthocyanidins, flavanols and phenolic acids which in laboratory studies have reported to promote antioxidant enzyme formation, reduces excess inflammation, slow cancer cell proliferation and promote apoptosis. Evidence from epidemiological studies on the effect of tea consumption on prostate cancer (CaP) incidence has been conflicting. We analysed data from 25 097 men within the intervention arm of the 155 000 participant Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Histologically confirmed cases of prostate cancer were reported in 3088 men (12·3 %) during the median 11·5 year follow-up. Tea consumption was assessed with a FFQ. Baseline characteristics were compared between groups using χ2 and Kruskal-Wallis tests. Cox regression models were used to assess associations between tea intake and CaP incidence. There was no statistical difference between the risk of CaP between men who never drank tea to those who drank tea at any quantity. Amongst tea drinkers, those in the highest third of consumption group had a small but significantly lower risk compared with those in the lowest third (11·2 % v. 13·2 % hazard ratio 1·16; (95 % CI 1·05, 1·29), P = 0·004). This pattern persisted with adjustments for demographics and lifestyle. In conclusion, among tea drinkers, there was a small positive association between drinking tea and a reduced risk of prostate cancer. It does not support starting to drink tea, if men previously did not, to reduce the risk. Further research is needed to establish whether tea is justified for future prospective nutritional intervention studies investigating CaP prevention.
    Language English
    Publishing date 2021-09-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 280396-3
    ISSN 1475-2662 ; 0007-1145
    ISSN (online) 1475-2662
    ISSN 0007-1145
    DOI 10.1017/S0007114521003664
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Medical treatment of renal cancer: new horizons.

    Greef, Basma / Eisen, Tim

    British journal of cancer

    2016  Volume 115, Issue 5, Page(s) 505–516

    Abstract: Renal cell carcinoma (RCC) makes up 2-3% of adult cancers. The introduction of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin inhibitors in the mid-2000s radically changed the management of RCC. These targeted treatments superseded ... ...

    Abstract Renal cell carcinoma (RCC) makes up 2-3% of adult cancers. The introduction of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin inhibitors in the mid-2000s radically changed the management of RCC. These targeted treatments superseded immunotherapy with interleukin-2 and interferon. The pendulum now appears to be shifting back towards immunotherapy, with the evidence of prolonged overall survival of patients with metastatic RCC on treatment with the anti-programmed cell death 1 ligand monoclonal antibody, nivolumab. Clinical prognostic criteria aid prediction of relapse risk for resected localised disease. Unfortunately, for patients at high risk of relapse, no adjuvant treatment has yet shown benefit, although further trials are yet to report. Clinical prognostic models also have a role in the management of advanced disease; now there is a pressing need for predictive biomarkers to direct therapy. Treatment selection for metastatic disease is currently based on histology, prognostic group and patient preference based on side effect profile. In this article, we review the current medical and surgical management of localised, oligometastatic and advanced RCC, including side effect management and the evidence base for management of poor-risk and non-clear cell disease. We discuss recent results from clinical trials and how these are likely to shape future practice and a renaissance of immunotherapy for renal cell cancer.
    MeSH term(s) Biomarkers, Tumor/metabolism ; Carcinoma, Renal Cell/pathology ; Carcinoma, Renal Cell/therapy ; Humans ; Kidney Neoplasms/pathology ; Kidney Neoplasms/therapy ; Neoplasm Metastasis ; Prognosis ; Survival Rate
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2016-08-23
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/bjc.2016.230
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Corrigendum: VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function.

    Briston, Thomas / Stephen, Jenna M / Thomas, Luke W / Esposito, Cinzia / Chung, Yuen-Li / Syafruddin, Saiful E / Turmaine, Mark / Maddalena, Lucas A / Greef, Basma / Szabadkai, Gyorgy / Maxwell, Patrick H / Vanharanta, Sakari / Ashcroft, Margaret

    Frontiers in oncology

    2021  Volume 11, Page(s) 740273

    Abstract: This corrects the article DOI: 10.3389/fonc.2018.00388.]. ...

    Abstract [This corrects the article DOI: 10.3389/fonc.2018.00388.].
    Language English
    Publishing date 2021-09-23
    Publishing country Switzerland
    Document type Published Erratum
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.740273
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function.

    Briston, Thomas / Stephen, Jenna M / Thomas, Luke W / Esposito, Cinzia / Chung, Yuen-Li / Syafruddin, Saiful E / Turmaine, Mark / Maddalena, Lucas A / Greef, Basma / Szabadkai, Gyorgy / Maxwell, Patrick H / Vanharanta, Sakari / Ashcroft, Margaret

    Frontiers in oncology

    2018  Volume 8, Page(s) 388

    Abstract: Dysregulated mitochondrial function is associated with the pathology of a wide range of diseases including renal disease and cancer. Thus, investigating regulators of mitochondrial function is of particular interest. Previous work has shown that the von ... ...

    Abstract Dysregulated mitochondrial function is associated with the pathology of a wide range of diseases including renal disease and cancer. Thus, investigating regulators of mitochondrial function is of particular interest. Previous work has shown that the von Hippel-Lindau tumor suppressor protein (pVHL) regulates mitochondrial biogenesis and respiratory chain function. pVHL is best known as an E3-ubiquitin ligase for the α-subunit of the hypoxia inducible factor (HIF) family of dimeric transcription factors. In normoxia, pVHL recognizes and binds hydroxylated HIF-α (HIF-1α and HIF-2α), targeting it for ubiquitination and proteasomal degradation. In this way, HIF transcriptional activity is tightly controlled at the level of HIF-α protein stability. At least 80% of clear cell renal carcinomas exhibit inactivation of the
    Language English
    Publishing date 2018-10-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2018.00388
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top